Leukocyte Adhesion Deficiency Type I – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Leukocyte Adhesion Deficiency Type I Market Outlook

Thelansis’s “Leukocyte Adhesion Deficiency Type I Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Leukocyte Adhesion Deficiency Type I treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Leukocyte Adhesion Deficiency Type I Overview

Leukocyte adhesion deficiency type I (LAD-I), a subtype of LAD defined in the terminology, is characterized by recurring bacterial infections that pose a life-threatening risk. Typically, the initial symptoms manifest during infancy or early childhood. Affected individuals frequently experience recurrent and life-threatening bacterial infections affecting the skin, mouth, and respiratory system. Delayed separation of the umbilical cord is a common occurrence. Skin infections may progress to the formation of extensive ulcers. In later stages of the condition, severe periodontitis often arises, leading to premature tooth loss. Notably, there is a lack of typical signs such as swelling, redness, heat, or pus in the infected areas. LAD-I arises due to mutations in the ITGB2 gene located at 21q22.3. This gene encodes for beta-2-integrin, known as CD18, which plays a vital role in facilitating the firm adhesion of leukocytes to the endothelium. The severity of the disease is closely linked to the extent of deficiency in CD18. Diagnosis hinges on comprehensive blood counts that reveal an elevated number of neutrophils, known as neutrophilic leukocytosis. Flow cytometric analyses show reduced expression of CD18 on leukocytes. Genetic tests for mutations in the ITGB2 gene are performed to confirm the diagnosis. Differential diagnoses include IRAK-4 deficiency, autosomal dominant hyperIgE syndrome, chronic granulomatous disease, other primary immunodeficiencies, and leukemoid reactions. The prognosis depends on the disease's severity. In severe cases of LAD-I, patients face a high risk of succumbing to infections within the first two years of life unless they undergo hematopoietic stem cell transplantation. Conversely, individuals with a moderate form of the condition have a better chance of surviving into adulthood. The survival rate following bone marrow transplantation is approximately 75%.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: